Trial Profile
A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Daratumumab/hyaluronidase (Primary) ; Diphenhydramine; Diphenhydramine; Methylprednisolone; Methylprednisolone; Montelukast; Paracetamol; Paracetamol
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational
- Sponsors Janssen Pharmaceutical KK
- 13 Apr 2023 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 Planned End Date changed from 31 Oct 2022 to 31 Aug 2023.
- 02 Dec 2021 Planned End Date changed from 29 Oct 2021 to 31 Oct 2022.